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Abstract
Background: Anti-leishmanial drug regimens that include a single dose AmBisomeH could be suitable for eastern African
patients with symptomatic visceral leishmaniasis (VL) but the appropriate single dose is unknown.
Methodology: A multi-centre, open-label, non-inferiority, randomized controlled trial with an adaptive design, was
conducted to compare the efficacy and safety of a single dose and multiple doses of AmBisomeH for the treatment of VL in
eastern Africa. The primary efficacy endpoint was definitive cure (DC) at 6 months. Symptomatic patients with
parasitologically-confirmed, non-severe VL, received a single dose of AmBisomeH 7.5 mg/kg body weight or multiple doses,
7 times 3 mg/kg on days 1–5, 14, and 21. If interim analyses, evaluated 30 days after the start of treatment following 40 or
80 patients, showed the single dose gave significantly poorer parasite clearance than multiple doses at the 5% significance
level, the single dose was increased by 2?5 mg/kg. In a sub-set of patients, parasite clearance was measured by quantitative
reverse transcriptase (qRT) PCR.
Principal Findings: The trial was terminated after the third interim analysis because of low efficacy of both regimens. Based
on the intention-to-treat population, DC was 85% (95%CI 73–93%), 40% (95%CI 19–64%), and 58% (95%CI 41–73%) in
patients treated with multiple doses (n = 63), and single doses of 7?5 (n = 21) or 10 mg/kg (n = 40), respectively. qRT-PCR
suggested superior parasite clearance with multiple doses as early as day 3. Safety data accorded with the drug label.
Conclusions: The tested AmBisomeH regimens would not be suitable for VL treatment across eastern Africa. An optimal
single dose regimen was not identified.
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Introduction
Visceral leishmaniasis (VL) is a life-threatening disease and a
major health burden in developing countries [1,2,3]. WHO
estimates there are approximately 0.2–0.4 million cases of VL
annually; and more than 90% of global VL cases occur in six
countries: India, Bangladesh, Sudan, South Sudan, Ethiopia and
Brazil [1]. In eastern Africa approximately 30,000 people develop
symptomatic VL and 4,000 die every year [3,4].
For decades, the mainstay of VL treatment in eastern Africa has
been antimonials such as sodium stibogluconate (SSG), but this
treatment is cardiotoxic [5] and requires a 4-week hospitalisation
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imposing a huge economic burden on families [6]. Monotherapy
with intramuscular paromomycin (PM) for 3 weeks was shown to
be less efficacious in eastern Africa [7] than in Asia [8], but a 17-
day treatment with a combination of SSG and PM showed good
efficacy and is now recommended as first-line treatment by WHO.
However, this treatment also requires a relatively long treatment
course and twice daily injections [8]. Currently, the safest anti-
leishmanial drug is AmBisomeH, a liposomal amphotericin B
formulation with significantly diminished renal toxicity [9]. In
trials in India, cure rates of around 90% were obtained with single
AmBisomeH doses of 5 mg/kg [9]. In addition, 95% efficacy was
achieved with higher single doses (10 mg/kg) or when used in
combination with miltefosine or paromomycin [10]. Although
licensed and recommended for first-line treatment of VL in
immunocompetent patients [11], AmbisomeH use in eastern Africa
has been mostly limited to second line treatment in a few centres
mainly due to its high cost and cold storage requirements [12]. A
small study with AmBisomeH conducted in Kenya indicated
higher doses were required than had been used in studies in India.
Doses of 2 mg/kg given 3, 5, or 7 times to groups of 10 patients
resulted in cure rates of 20%, 90%, and 100% respectively [13].
The aim of this study was to determine the minimum efficacious
and safe single dose for the likely future use of the drug as part of a
shorter course of treatment regimen for eastern African VL
patients. The trial was undertaken with the goal of ultimately
identifying a short and simplified treatment regimen that includes
AmBisomeH. Such a regimen will improve patient compliance and
will have the advantage of a reduced cost.
Methods
The study design and protocol have been published, in
compliance with CONSORT requirements [14]. The protocol
was approved in Ethiopia, Sudan and UK by the authors’
Institutional and National Ethics Committees. These committees
were: the Research Ethics Institutional Review Board of the
Faculty of Medicine – Addis Ababa University; The Institutional
Review Board of the University of Gondar; the National Ethics
Review Committee (NERC) at the Ethiopian Science & Technol-
ogy Commission (ESTC); the Health Research Ethics Committee
of the Institute of Endemic Diseases (University of Khartoum) and
the Directorate of Health Research in the Federal Ministry of
Health (Sudan); and the Ethics Committee of the London School
of Hygiene and Tropical Medicine. The study was conducted in
accordance with the declaration of Helsinki, ICH GCP guidelines,
and all applicable legal requirements. All study subjects partici-
pated in the study voluntarily, and signed a written ‘Informed
Consent Form’ (ICF). The parents or guardians of study
participants under the age of 18 years provided written informed
consent on their behalf. In addition, minors (age 12–17 years)
signed a written assent form. The study was registered at www.
clinicaltrials.gov (Clinical Trials Registration number
NCT00832208) prior to trial initiation and patient recruitment.
Study design
The study was designed as a multi-centre, open-label, non-
inferiority, randomized controlled trial, using a sequential-step
design to evaluate the efficacy and safety of a single dose treatment
regimen of intravenous AmBisomeH (either 7.5, 10.0, 12.5 or
15.0 mg/kg body weight) compared to the reference multiple dose
regimen currently approved in the USA: 3 mg/kg body weight on
days 1 to 5, 14, and 21. The single dose tested in the first cohort
was 7?5 mg/kg body weight (figure 1, the consort flowchart). Two
interim analyses were planned, after enrolment of 20 and 40
patients per arm, for early detection of inefficacious single doses,
based on parasite clearance at day 30 (figure 2) and/or worsening
clinical conditions. If the stopping rule was met, the single dose
was increased by 2?5 mg/kg and recruitment into the two arms
restarted. The multiple dose treatment remained the same
throughout. Non-responders to treatment were considered treat-
ment failures and received rescue medication (multiple dose
AmBisomeH regimen for single-dose failures and SSG for multiple
dose failures).
Study population
Patients with age of at least 4 years, confirmed HIV-negative,
parasitologically-confirmed non-severe VL, were enrolled in three
centres: (1) Gondar University Hospital, Amhara Regional State,
Northern Ethiopia; (2) Arba Minch Hospital, Gamo Gofa Zone,
Southern Nations, Nationalities and Peoples Regional State,
Southern Ethiopia; and per protocol amendment (3) Ministry of
Health Hospital, Kassab, Gedaref State, Eastern Sudan from May
2009 to September 2010. Exclusion criteria were signs/symptoms
of severe VL (patients who were very weak, unable to walk,
bleeding, jaundiced, suffering from sepsis and other concomitant
infections/illnesses); anti-leishmanial or unlicensed investigational
treatments within six months; underlying chronic disease such as
severe cardiac, pulmonary, renal, or hepatic impairment; serum
creatinine outside the normal range; liver function tests more than
3 times the normal range; platelet count less than 40,000/mm3;
known alcohol abuse; pregnancy or lactation; concomitant acute
drug usage for malaria and bacterial infection; pneumonia within
last 7 days; known hypersensitivity to AmBisomeH or amphotericin
B; any other condition which may invalidate the trial.
Interventions
On pre-specified treatment days, AmBisomeH dosage was
calculated according to body weight. Preparation included
reconstitution with sterile water for injection and filtration
according to the manufacturer’s instructions. Administration was
by slow intravenous infusion in 5% dextrose solution. During
infusion, patients were closely observed with regular monitoring of
vital signs (blood pressure and pulse). A test dose was administered
in the first 10 minutes of infusion, and the patients carefully
Author Summary
Visceral leishmaniasis is a potentially fatal disease which
affects 0.2–0.4 million people every year, principally in
South-East Asia, Latin America or Eastern Africa. Currently
the safest drug in use is AmBisomeH, which cures 90% of
patients in India at 5 mg/kg, and is even more effective at
higher doses (10 mg/kg) or in combination with miltefo-
sine or paromomycin. These regimens have been shown to
be equally cost-effective in India. However, the drug
requires a cold chain for storage and reconstitution prior
to injection. Although it is licensed for use in eastern
Africa, in practice it is mainly used as a second-line
treatment. A small study carried out in Kenya indicated
that a higher dose is necessary in eastern Africa in contrast
to Asia. This study aimed to determine the minimum single
dose that is safe and effective for treatment of eastern
African VL patients so as to be used in simplified treatment
regimens. However, the tested regimens were found to be
ineffective, and an optimal single dose that could
potentially be used in simplified treatment regimens was
not identified.
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observed for 30 minutes. The time of treatment and dosage was
recorded.
Randomisation and blinding
Patients were randomized to receive either treatment using a
computer-generated randomisation list, stratified by site. Individ-
ual treatment allocations were placed in sealed, opaque envelopes
which were opened after a patient had been entered into the trial.
It was not possible to blind patients or treating physicians due to
the nature of the intervention.
Endpoints
Primary (definitive/final cure) and secondary (initial cure)
efficacy endpoints were determined by parasitological assessment,
as the most objective and consistent method across treatment
centres at six months follow-up and at Day 30, respectively. Day
30 was considered as the end of treatment time point for initial
cure assessment. Definitive cure was defined as absence of
parasites in tissue aspirates (bone marrow, lymph node or spleen)
with no relapse of signs and symptoms of VL during six months
follow-up. Initial cure was defined on day 30 by absence of
parasites in tissue aspirates. For patients with detectable parasites
at initial cure assessment, clinical and biological assessments were
used, in addition to parasitological results, to ascertain the need for
rescue treatment at the end of study treatment at the discretion of
the treating clinician, according to the protocol. Patients with a
presence of parasites at initial assessment of cure but who were
clinically well were invited to return after one month to further
assess their status and need for rescue treatment. Patients who did
not clear parasites at end of treatment but did by six months
follow-up, in the absence of a requirement for additional rescue
treatment, were classified as treatment successes at six months as
patients who were slow responders, in line with previous trials in
the region [7]. Assessment of safety involved monitoring vital signs,
documentation of patients’ complaints about the treatments, and
haematological and biochemical measurements evaluated on days
2 to 5, 7, 14, 21 and 30, and at 3 and 6 months. Treatment
emergent adverse events (TEAE) were classified according to the
Medical Dictionary for Regulatory Activities (MedDRA). Treat-
ment emergent events were those with onset between day 1 of
treatment and day 60 inclusive.
Peripheral Blood Parasitaemia: In Kassab, per protocol
amendment, peripheral blood samples were analysed for parasite
load in a subset of 5 consenting patients in each of the 10 mg/kg
single dose and multiple dose arms. For this, a validated
quantitative reverse-transcriptase polymerase-chain-reaction
(qRT-PCR) method targeting Leishmania 18S ribosomal RNA
was used [15]. Genetic material was extracted using a modified
Boom-method [15,16,17]. qRT-PCR analysis using a Bio-Rad
CFX-96 real-time machine (Bio-Rad, Veenendaal, the Nether-
lands) was performed at Koninklijk Instituut voor de Tropen
(KIT).
Figure 1. Patient flow chart. Consort Patient flow chart: AmBisomeHmulti dose vs. single dose, ITT Intention to treat, PP per protocol, LTFU Lost to
Follow-up.
doi:10.1371/journal.pntd.0002613.g001
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Sample size
For the primary endpoint comparison, 120 patients per
arm would provide 80% power to detect non-inferiority within
a margin of 10%, assuming 95% cure in the reference arm, a
one-sided alpha of 0?05 and 15% loss-to-follow-up. In interim
analyses, 20 patients per arm would provide 90% power to detect
a difference of at least 35% in parasite clearance rate at day
30, assuming 95% cure in the reference arm and a two-sided
alpha of 0.05. With 40 patients per arm, there would be 90%
power to detect a difference of at least 25% under the same
assumptions.
Statistical analysis
Interim analyses were based on day 30 cure in the Intention-to-
Treat (ITT) population. Decision-making at each interim analysis
was based on a test of difference between the parasite clearance
rates in the single dose arm and multiple dose arms. If the single
dose arm showed significantly poorer efficacy (P,0.05), the single-
dose was increased prior to re-starting recruitment. Patients
allocated to the multiple-dose arm for discontinued single-dose
comparisons were not included in comparisons of higher single
doses.
Key assumptions for the planned final analysis were not met due
to low efficacy in the multi-dose arm and the trial was terminated
prematurely (see Results). Cumulative data for each treatment
regimen were used to calculate the percentage of patients cured,
with exact binomial 95% confidence intervals (CI), at day 30 and 6
months follow-up in ITT and per-protocol (PP) analysis popula-
tions. Patients with missing outcome data were excluded from
analyses. For safety, the number and percentage of patients per
arm experiencing adverse events (AEs) were summarised, for AEs
with cumulative incidence higher than 10%. For parasite
clearance from peripheral blood, a linear mixed effects regression
model using the natural log-transformed parasite loads was applied
to estimate the time to clear 50% and 90% of parasites for each
individual. Model performance and significance were assessed by
analysis of variance (ANOVA).
Results
Baseline characteristics
The most commonly presenting VL symptoms were fever and
weight loss, followed by loss of appetite, abdominal swelling, and
cough; less commonly observed were epistaxis, diarrhoea, and skin
Figure 2. Summary of study design. Interim analyses were based on day 30 cure in the Intention-to-Treat (ITT) population. iv intravenous, mg/kg/
day milligram/kilogram body weight/day.
doi:10.1371/journal.pntd.0002613.g002
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lesions. Other characteristics of patients at entry to the trial are
summarized in Table 1. Overall, 82% of patients weremale and about
half were children. About two thirds of patients were underweight
or severely underweight. Mean haemoglobin concentrations were
,8?0 g/dl, and anaemia was common, but neither baseline
laboratory parameters nor vital signs suggested any major difference
among dose groups. Baseline characteristics were generally compa-
rable in the multiple and the 10 mg/kg single dose group, whereas the
smaller 7?5 mg/kg dose group showed some imbalances: on average,
patients in this group were older and accordingly had higher body
weight and larger spleen size, but also had the highest baseline
parasitaemia. Patients were younger in Kassab (10?565?0 years) than
in Gondar (20?966?3) or Arba Minch (17?4610?2 in) and more often
female in Kassab (33?3%) than in Gondar (10?5%) or Arba Minch
(12%). In Arba Minch, they were more often normal weight (42?0%)
than in Gondar (21?1%) or Kassab (28?6%).
Efficacy
In the first section of Table 2, parasite clearance rates at day 30
are shown for the three interim analyses. Summary data for the
parasite clearance rate at day 30 and the cure rate at 6 months are
shown for all patients and for those treated at each of the 3 centres.
The IC and DC rates with the standard multiple dose treatment
were both 85%. IC rates with single doses of 7?5 and 10 mg/kg
were 50% and 73%, respectively; and DC rates were lower, at
40% and 58%, respectively. However, there were variations in
treatment response between treatment centres, with poor efficacy
in Kassab and Gondar, particularly with single doses. By contrast,
at Arba Minch, the multiple doses as well as the single dose of
10 mg/kg resulted in complete cure, and treatment failures were
observed with the 7?5 mg/kg dose only. All non-responders were
cured after receiving rescue medication.
Early termination
For the first interim analysis, comparing the 7?5 mg/kg single
dose to the multiple dose regimen with 20 and 18 patients per arm,
respectively, in the two Ethiopian sites, the stopping rule was met
(Table 2: Fisher’s exact test, p = 0?015). The single dose was
increased to 10 mg/kg, and recruitment restarted at both
Ethiopian sites and in an additional site, Kassab, Sudan. There
was no significant difference in efficacy found at the next interim
analysis comparing 10 mg/kg to the multiple dose arm
(p = 0?748), but when 44 patients had been recruited into the
multiple dose and 40 patients into the 10 mg/kg single-dose arm,
the third interim analysis indicated unexpectedly low initial cure
rates in both arms; 84% in the multiple dose and 73% in the
single-dose arm. The stopping rule was not met (chi-squared test,
p = 0.196), but based on the observed poor efficacy overall, and
following discussions with the Data Safety and Monitoring Board
(DSMB) and investigators, the sponsor terminated the trial.
Table 1. Baseline data on patient demographics, clinical characteristics and laboratory values.
Multiple dose 21 mg/kg
N=63
Single dose 7.5 mg/kg
N=21
Single dose 10 mg/kg
N=40
Age in years Mean (SD) 16 (9.0) 21 (9.2) 14 (7.4)
Children (4–17 y), n (%) 37 (59) 4 (19) 25 (63)
Adults ($18 y), n (%) 26 (41) 17 (81) 15 (37)
Sex Female, n (%) 10 (16) 2 (11) 10 (25)
Male, n (%) 53 (84) 19 (91) 30 (75)
Spleen size in cm Mean (SD) 9.5 (5.3) 12.0 (6.0) 9.1 (5.3)
Nutritional status{ Weight [kg], mean (SD) 36 (14.5) 44 (12.2) 33 (14.4)
Severe underweight, n (%) 18 (29) 9 (43) 11 (28)
Underweight, n (%) 22 (35) 7 (33) 17 (43)
Normal weight, n (%) 22 (35) 5 (24) 12 (30)
Hemoglobin (g/dl) Mean (SD) 7.9 (1.7) 7.7 (1.6) 7.7 (1.4)
AST Mean (SD) 52 (27.1) 48 (28.5) 54 (29.0)
ALT Mean (SD) 32 (20.7) 35 (21.3) 33 (20.0)
Parasite Count (log scale) 6+, n (%) 2 (3) 2 (10) 0
5+, n (%) 7 (11) 5 (23) 7 (18)
4+, n (%) 14 (22) 6 (29) 4 (10)
3+, n (%) 15 (23) 4 (19) 9 (22)
2+, n (%) 11 (17) 4 (19) 9 (22)
1+, n (%) 12 (20) 0 10 (25)
0 or missing, n (%) 2* (3) 0 1** (3)
Data are n (%) or means (SD). AST aspartate aminotransferase, ALT alanine aminotransferase.
{classified using weight for height and BMI for age in those aged #19 years and BMI in those aged .19: normal if 22SD# weight for height or BMI for age ,+1SD or
18.5#BMI,25.0; underweight if 23SD# weight for height or BMI for age ,22SD or 16.0#BMI,18.5; severely underweight if weight for height or BMI for age ,23SD
or BMI,16.0.
*1 case of unconfirmed VL with no parasites detected (major protocol deviation, excluded from analysis) and one case of no parasite count recorded on a log scale in
which VL was confirmed by lymph node aspirate.
**no parasite count recorded on a log scale in which VL was confirmed by lymph node aspirate.
doi:10.1371/journal.pntd.0002613.t001
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At that time, a total of 124 patients had been enrolled into the
trial; 63 had received the multiple dose regimen, 20 patients
received a single dose of 7?5 mg/kg dose and 41 patients received
a single dose of 10 mg/kg (figure 1).
Safety
TEAE were common regardless of dose regimen. Severity was
mostly mild or moderate and only about 2% of TEAE were rated
severe, mostly with respect to laboratory measurements. There
was one non-fatal SAE, a pneumonia deemed unlikely related to
the drug, and one death due to snakebite. AEs for which
relatedness could not be excluded are listed in Table 3. These
potential adverse drug reactions were seen in all the three dose
groups and occurred in both the multiple and the higher single
dose groups with similar frequencies.
Pharmacodynamics
At baseline, semi-quantitative microscopy counts on bone
marrow aspirates correlated well with parasite loads in peripheral
blood when assessed by qRT-PCR (R2: 0?77, p,0?01). Mean
natural log-normalized parasite loads (P) were comparable in the
single and multiple dose groups (6?4 lnP/mL, 95%CI: 4?6–8?2
versus 5?1 lnP/mL, 95%CI: 3?3–6?8; p = 0?358) at baseline. Three
out of the 5 patients of each group had baseline blood parasite
loads .50 per mL and these had clearance rates assessed and
modelled over the first 7 days. Mean parasite clearance rates were
significantly different between the single and the multiple dose
group (0?35 per day, 95%CI: 0?00–0?70 versus 1?14 per day,
95%CI: 0?78–1?50; p = 0?012) as early as day 3 (Figure 3),
corresponding to mean parasite elimination half-lives of 1?97 days
(95% CI: 0?99–278) for the single-dose group and 0?61 days
(95%CI: 0?46–0?89) for the multiple dose group. Time required
for 90% parasite clearance for single-dose and multiple-dose
groups was estimated at 6?55 (95% CI: 3?29–923) and 2?02 (95%
CI: 1?53–2?95) days, respectively. One patient in the single dose
group had a low blood parasite load at baseline, which increased
until day 30, but was no longer detectable after rescue treatment.
Discussion
We investigated the efficacy of AmBisomeH given as multiple or
single dose regimens for treatment of VL in eastern Africa. The
aim was to determine the minimum efficacious dose and safety of
treatments in HIV-uninfected patients. However, the study had to
be prematurely terminated due to unacceptably low efficacy in
both the single and multiple dose treatment arms, with a cure rate
of only 85% in the multiple-dose arm. Adverse effects of treatment
in this study were in line with the current drug label.
The overall low efficacy was unexpected, as total doses of
10 mg/kg and above resulted in DC rates of at least 90% in a trial
in Kenya [13]. The trial was not powered for data analysis by
geographical location (centre) and the results may have been due
to chance, but both the 10 mg/kg single dose and 21 mg/kg
multiple dose regimens appeared to work very well in the small
number of patients treated in Arba Minch Hospital (southern
Ethiopia). We have little explanation for the overall poor response
seen in this study or for the observed geographical variations.
Previously, similar geographical variation in treatment response in
these three sites was seen for daily doses of 11 mg/kg body weight
paromomycin base over 21 days [7], a regimen which had also
proven efficacious in India [18]. Methodological bias is unlikely in
Table 2. Interim analyses and non-comparative efficacy analysis for primary (day 210) and secondary (day 30) end points.
Multiple dose Single dose Single dose
763 mg/kg 7.5 mg/kg 10 mg/kg
Parasite clearance at day 30 (IC) No of patients(N) No. cured(n) (%) 95% CI* N n (%) 95% CI* N n (%) 95% CI*
Interim analysis 1` 18 16 (89) 65–99 20 10 (50) 27–73 - - -
Interim analysis 2** 25 19 (74) 55–91 - - - 20 16 (80) 56–94
Interim analysis 31 44 37 (84) 70–93 - - - 40 29 (73) 56–85
Cure at Day 30
Overall 62w 53 (85) 74–93 20 10 (50) 27–73 40 29 (73) 56–85
Kassab, Sudan 18 16 (89) 65–99 - - - 18 13 (72) 47–90
Gondar, Ethiopia 20 13 (65) 41–85 9 2(22) 3–60 9 3 (33) 7–70
Arba Minch, Ethiopia 24 24 (100) 86–100{ 11 8 (73) 39–94 13 13 (100) 75–100{
Cure at Day 210 (6 months follow-up)
Overall 54w 46 (85) 73–93 20 8 (40) 19–64 40 23 (58) 41–73
Kassab, Sudan 17 13 (76) 50–93 - - - 18 7 (39) 17–64
Gondar, Ethiopia 14 10 (71) 42–92 9 1 (11) ,1–48 9 3 (33) 7–70
Arba Minch, Ethiopia 23 23 (100) 83–100{ 11 7 (64) 31–89 13 13 (100) 75–100{
Intention-to-Treat and Per-Protocol complete-case analysis populations were identical at day 30 & day 210.
*Exact binomial 95% confidence interval (CI).
{One-sided 97.5% confidence interval.
`Multiple versus 7.5 mg/kg single dose; p-value = 0.015 (Fisher’s exact test): Dose escalation rule met; increase dosage to 10 mg/kg & continue recruitment.
**Multiple versus 10 mg/kg single dose; p value = 0.748 from chi-square test of difference between arms: Dose escalation rule not met; continue recruitment (same
dosage in single-dose arm).
1Includes patients in Interim analysis 2. Multiple versus 10 mg/kg single dose; p-value = 0.196 from chi-square test of difference between arms: Dose escalation rule not
met; concerns arose regarding low cure in each arm and recruitment not continued.
w8 patients lost to follow-up by day 210 (all from the multiple-dose arm).
doi:10.1371/journal.pntd.0002613.t002
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this randomized trial, but differences in base line patient
characteristics between the three trial sites could have possibly
introduced bias, leading to variation in treatment response. In
Arba Minch, about 16% of patients were severely underweight, as
compared to more than twice as many in the two sites with poorer
responses. However, in all sites, between 58% and 79% of patients
were underweight or severely underweight. As poor treatment
response was not restricted to the severely underweight patients
only, mechanisms are likely to be more complex. Furthermore, the
single dose trial in India did not have stricter inclusion/exclusion
criteria (it included patients with severe malnutrition) and had a
population of patients comparable with ours in terms of mean age
and body weight [18]. It is possible that other factors, such as
haemoglobin and immunity, may play a role; however, it is
unlikely that they can account for the large differences seen
between India and eastern Africa or within Africa. The poor
response may relate to characteristics of either the host or the
parasite or a combination of both. Of note, the disease ecology in
Kenya and southern Ethiopia is similar in terms of transmission
cycle, as is also the case between the north Ethiopia and eastern
Sudan VL [19]. Regarding the parasite; susceptibility to
treatments (e.g. SSG) is known to be different in Africa and India,
although development of resistance is unlikely to account for the
poor response in this study. In Africa, resistance has generally not
been an issue and amphotericin B has not been widely used. Of
the two closely related Leishmania species of the L. donovani
complex that cause VL (L. donovani and L. infantum/chagasi),
only the former exists in eastern Africa. However, recent studies
employing microsatellite markers have revealed the existence of
genetically varied populations of L. donovani in south and north
Ethiopia [20]. Whether such genetic variation accounts for the
difference in treatment outcomes remains to be determined.
Currently ongoing drug susceptibility testing may give some clues.
Due to early termination of the study, results were not conclusive
regarding the primary objective, i.e. the efficacy comparison of
single and multiple doses. However, pharmacodynamic data
suggests a benefit of multiple doses on peripheral parasite
clearance. On day 3 of treatment, differences in peripheral
Table 3. Infusion-related and drug-related treatment emergent AEs.
Multiple, 21 mg/kg Single, 7.5 mg/kg Single, 10 mg/kg
Total number of patients randomised N=63 N=21 N=40
Number of patients with any infusion-related AE, n (%) 22 (35) 4 (19) 17 (43)
Infusion related AE by MedDRA preferred term
Vomiting 2 (3) 0 (0) 0 (0)
Chills 0 (0) 0 (0) 1 (3)
Pyrexia 17 (27) 0 (0) 14 (35)
Arthalgia 4 (6) 3 (14) 1 (3)
Back Pain 1 (2) 1 (5) 2 (5)
Hypertension 1 (2) 0 (0) 0 (0)
Number of patients with TEADR, n (%)* (with cumulate incidence of 10%
or greater in any group)
56 (89) 20 (95) 36 (90)
TEADR by MedDRA preferred term
Anaemia 3 (5) 1 (5) 7 (18)
Thrombocytosis 5 (8) 0 (0) 6 (15)
Pyrexia 20 (32) 1 (5) 14 (35)
Alanine aminotransferase increased 17 (27) 13 (62) 11 (28)
Asparate aminotransferatase increased 22 (35) 14 (67) 13 (33)
Blood creatinine increased 9 (14) 1 (5) 4 (10)
Blood magnesium abnormal 2 (3) 0 (0) 4 (10)
Blood magnesium decreased 10 (16) 9 (43) 6 (15)
Blood potassium decreased 4 (6) 9 (43) 1 (3)
Blood sodium decreased 8 (13) 7 (33) 1 (3)
Hypermagnesaemia 6 (10) 0 (0) 4 (10)
Hypokalaemia 30 (48) 4 (19) 16 (40)
Hypomagnesaemia 7 (11) 0 (0) 8 (20)
Arthralgia 4 (6) 3 (14) 1 (3)
Azotaemia 8 (13) 0 (0) 8 (20)
Renal impairment 0 (0) 0 (0) 4 (10)**
TEADR= treatment emergent adverse drug reaction; treatment emergent = onset between day 1 and day 60 inclusive; adverse drug reaction if investigator judged
relationship to treatment as ‘‘probable’’, ‘‘possible’’ or ‘‘unlikely’’.
*This includes patients with infusion related reactions.
**Renal impairment: 3 mild cases and 1 moderate as graded by investigator, all resolved during study period.
doi:10.1371/journal.pntd.0002613.t003
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parasite clearance were significant, even though total administered
doses up to this time point were comparable in both arms (10
versus 9 mg/kg, respectively). This suggests a possible role for the
frequency of administration. This would need to be confirmed by
further studies, but is supported by the relatively high cure rate
achieved in single dose patients rescued by additional standard
multiple dose regimen. Even in India, where efficacy of single
doses was shown to be good, it was lower than multiple dose
regimens [21,22]. In eastern Africa, there might be no optimal
montherapy dosing regimen of AmBisomeH for VL but combina-
tion therapies including AmBisomeH are still of interest and under
investigation [23]. In this respect, qRT-PCR results are interest-
ing, although its use in Africa might be hampered by relatively low
blood parasitaemia at baseline and the prohibitive cost of the test.
More sensitive prognostic pharmacodynamic biomarkers, appli-
cable in all patients, are needed to monitor treatment response.
Conclusion
AmBisomeH in single doses of up to 10 mg/kg is suboptimal for
eastern African VL patients. A higher dose of 21 mg/kg adminis-
tered in multiple doses was also far less effective than anticipated. In
a small number of patients, no treatment failures occurred in
patients from south Ethiopia treated in Arba Minch Hospital either
with 10 mg/kg single dose or 21 mg/kg divided doses. The tested
AmBisomeH regimens would not be suitable for VL treatment
across eastern Africa, and an optimal single dose that could be
included in shorter and simplified treatment regimens of anti-
leishmanial drugs across all VL endemic regions of eastern Africa
was not identified. Efficacy of AmBisomeHfor the treatment of VL in
eastern Africa was variable and overall lower than in India.
Supporting Information
Checklist S1 CONSORT checklist.
(DOC)
Text S1 Study protocol.
(PDF)
Acknowledgments
Our thanks go to: 1) the Food, Medicines, and Health Care Administration
& Control Authority (FMHACA) of Ethiopia, 2) the Federal Ministry of
Health – Government of Ethiopia, 3) the Ministry of Gedaref state, Sudan,
4) The Regional Health Bureaus in SNNP-RG (South Ethiopia) and
Amhara Regional State (north Ethiopia), 5) The College of Health Sciences
– Addis Ababa University, and 6) Institute of Endemic Diseases - Sudan.
We give a special recognition to the clinical monitors’ team and the Data
and Safety Monitoring Board.
Author Contributions
Conceived and designed the experiments: AH TE EAGK AMM MB MW
SE PGS. Performed the experiments: TW BMYWHal AAA ZH SY WHai
RK TPCD GJS. Analyzed the data: TE RO SE PGS AH EAGK RK
AMM TPCD GJS. Contributed reagents/materials/analysis tools: TPCD
GJS TE PGS. Wrote the paper: TE AH EAGK AMM PGS MW AMEH
SE.
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